Thursday, May 2, 2024
Home Biotech News Infections Page 9

Infections

    Featured posts

    Citius Pharma (CTXR) Corporate Presentation (Jan 2020).

    Biotech News Editor / Curator -
    In the above graphic, the catheter can get infected by bacteria and most typically see evidence of the infection (see gross graphic...
    steven boyd, biotech stock review

    Armistice Capital Master Fund Ltd., and Citius Pharma (CTXR).

    Biotech News Editor / Curator -
    April 2019 Offering On April 1, 2019, Citius entered into securities purchase agreements with institutional investors and accredited investors...
    candida auris, citius pharma, biotech stock review

    Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.

    Biotech News Editor / Curator -
    CRANFORD, N.J., May 13, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug...
    1...789Page 9 of 9

    Latest article

    Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

    Institutional Analyst Newsletter Editor / Curator -
    DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

    Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

    Infections Editor / Curator -
    Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!

    Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

    Infections Editor / Curator -
    CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.